Ipamorelin + CJC-1295 Stack: Safety, Monitoring, and Protocol

What Is the Ipamorelin and CJC-1295 Stack?

Ipamorelin is a synthetic pentapeptide that selectively activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a), triggering a pulse of endogenous growth hormone (GH) from the anterior pituitary. CJC-1295 is a modified form of growth hormone-releasing hormone (GHRH) that binds the GHRH receptor (GHRH-R) on somatotroph cells. Because the two peptides act on different receptors within the same pituitary cell, combining them produces a synergistic GH pulse that is consistently larger than either agent alone, based on rodent pituitary cell studies and the established physiology of GHRH-GHRP co-administration [1].

The combination is popular in anti-aging medicine, sports medicine, and compounding pharmacy settings. Prescribers typically pair it for patients seeking improvements in body composition, sleep quality, recovery, and lean mass preservation during caloric deficits.

How Each Peptide Works

Ipamorelin mimics ghrelin but with high receptor selectivity. Unlike older GHRPs such as GHRP-6, it does not meaningfully raise cortisol or prolactin at standard doses, a distinction confirmed in early human studies showing minimal endocrine side effects at doses up to 200 mcg [2]. The GH pulse produced by ipamorelin alone is modest and short-lived, peaking roughly 30 to 60 minutes after subcutaneous injection.

CJC-1295 extends and amplifies this response. The version with drug affinity complex (DAC) covalently binds albumin, extending its half-life to approximately 6 to 8 days and producing sustained baseline GH elevation rather than discrete pulses [3]. The version without DAC (also called modified GRF 1-29 or Mod GRF) acts more like native GHRH, with a half-life under 30 minutes and pulse-like kinetics that are better suited for combination with ipamorelin.

Why Clinicians Combine Them

In pituitary physiology, GHRH primes the somatotroph cell while a GHRP provides the triggering signal. Combining the two produces GH release that is several-fold greater than either stimulus alone, a relationship demonstrated in multiple in vitro models and confirmed in clinical GHRH-GHRP combination studies using sermorelin plus GHRP-2 [4]. The ipamorelin and CJC-1295 pairing applies the same principle using agents with more favorable selectivity profiles.

Evidence Base: What the Research Actually Shows

No published randomized controlled trial has tested the specific combination of ipamorelin and CJC-1295 in humans. This is a meaningful evidence gap. Clinicians and patients should understand what the available data can and cannot support.

Ipamorelin Human Data

A phase I study by Raun et al. Established that ipamorelin produced dose-dependent GH secretion in human volunteers with a clean side-effect profile, and that doses of 1 to 3 mcg/kg produced peak serum GH increases of roughly 5 to 10 ng/mL without significant cortisol or prolactin elevation [2]. That data supports ipamorelin's tolerability but does not address long-term use or combination dosing.

CJC-1295 Human Data

Teichman et al. Conducted a dose-escalation study of CJC-1295 in 66 healthy adults. Single subcutaneous doses of 30 to 120 mcg/kg elevated mean plasma GH 2- to 10-fold and sustained IGF-1 increases for up to 14 days at higher doses [3]. The study reported injection-site reactions in a small number of subjects and no serious adverse events, but it was not powered to detect metabolic harms and ran for only a short duration.

GHRH-GHRP Combination Evidence

The closest human analog is the combined GHRH-GHRP-2 protocol studied by Bowers and colleagues and used in IGF-1 deficiency research. Corpas et al. Showed that pulsatile GHRH administration in older men restored GH secretion patterns toward those of younger adults [5]. The general principle that dual-axis stimulation amplifies GH output is well-supported. Extrapolating this to the ipamorelin plus CJC-1295 pair is mechanistically sound but not directly proven.

What This Means Clinically

Practitioners using this stack are making a reasonable mechanistic inference, not following an evidence-based protocol. Informed consent should explicitly state that no RCT safety data exists for this specific combination, that IGF-1 elevation may exceed the physiologically normal range, and that downstream cancer-risk implications of sustained IGF-1 elevation remain unresolved in this context [6].

Safety Profile and Known Risks

The ipamorelin and CJC-1295 stack shares the class-level risk profile of growth hormone secretagogues. Adverse effects range from mild and transient to potentially serious. The severity and frequency of side effects are generally dose-dependent.

IGF-1 Elevation and Cancer Risk

Both peptides raise serum IGF-1 by increasing pulsatile GH output. Elevated IGF-1 is the primary safety concern for long-term use. Epidemiological data associate high-normal and above-normal IGF-1 with increased colorectal and prostate cancer risk [6]. The relationship is observational and does not prove causation in the peptide-use context. A supra-physiologic IGF-1, defined as a value above the age-adjusted 97.5th percentile on a validated assay, should trigger dose reduction or stack discontinuation.

Glucose Dysregulation

GH is a counter-regulatory hormone that reduces insulin sensitivity. Chronic GH elevation from frequent peptide dosing may raise fasting glucose and HbA1c over weeks to months. A 2023 review of GH therapy adverse effects noted that supraphysiologic GH exposure consistently worsens insulin resistance in both adults and adolescents [7]. Patients with pre-existing insulin resistance, metabolic syndrome, or type 2 diabetes face elevated risk and require tighter glucose monitoring.

Fluid Retention and Edema

Peripheral edema, joint stiffness (particularly carpal tunnel-like symptoms in the hands), and water retention are common early in therapy. These reflect GH's renal sodium-retaining effects. They typically resolve within 2 to 4 weeks as the body equilibrates to the new GH environment, or after dose reduction.

Injection-Site Reactions

Subcutaneous injections carry a low risk of local inflammation, lipodystrophy with repeated dosing at the same site, and, in non-sterile preparation conditions, infection. Compounded peptides are not subject to FDA manufacturing oversight equivalent to approved pharmaceuticals, raising contamination risk compared to commercial injectables [8].

Pituitary Desensitization

Continuous GHRH-R stimulation by CJC-1295 with DAC may blunt somatotroph responsiveness over time, a phenomenon observed with prolonged GHRH infusion in animal models. This is one mechanistic rationale for cycling the stack (8 to 16 weeks on, 4 to 8 weeks off) rather than using it continuously.

Monitoring Protocol: Labs, Timing, and Thresholds

Because no published monitoring guidelines exist specifically for this peptide combination, the framework below is derived from FDA-approved GH therapy monitoring recommendations, endocrine society guidance on IGF-1 surveillance, and standard metabolic monitoring adapted to this population [9].

Baseline Labs (Before Starting)

Every patient should have the following before the first injection:

• Serum IGF-1 (age- and sex-adjusted reference range)
• Fasting glucose and fasting insulin (calculate HOMA-IR)
• HbA1c
• Comprehensive metabolic panel (CMP)
• Lipid panel
• Thyroid-stimulating hormone (TSH)
• Sex hormone panel (total testosterone, LH, FSH, estradiol) where clinically relevant
• Prolactin (baseline for comparison, given ghrelin-pathway activation)
• PSA in men over 40

On-Cycle Monitoring (Weeks 8 and 12)

Repeat IGF-1 at 8 weeks. If IGF-1 exceeds the upper limit of the age-adjusted normal range, reduce the dose by 50% and recheck in 4 weeks. Do not continue at the same dose with a supra-normal IGF-1. Repeat fasting glucose and HbA1c at 12 weeks.

Maintenance Monitoring (Every 6 Months on Continuous Protocol)

• IGF-1
• Fasting glucose and HbA1c
• CMP (renal and hepatic function)
• Lipid panel
• PSA (men >40 years)

IGF-1 Target Range

The Endocrine Society's clinical practice guideline on adult growth hormone deficiency defines a therapeutic IGF-1 target of the age- and sex-adjusted middle third of the normal reference range, typically a standard deviation score (SDS) of 0 to +1 [9]. For peptide secretagogue users who are not GH-deficient, staying within the normal reference range (SDS <2) is the conservative approach that minimizes theoretical cancer-risk concern.

Dosing Protocol: Common Clinical Practice

The following reflects practitioner-reported protocols and mechanistic rationale rather than an approved prescribing guideline.

Ipamorelin Dosing

Standard starting doses range from 100 to 200 mcg per injection, administered subcutaneously. Many clinicians begin at 100 mcg once daily, dosed at bedtime to align with the physiologic nocturnal GH surge. Some protocols escalate to two or three daily injections (morning, pre-workout, and bedtime) for more aggressive GH stimulation, though this increases IGF-1 accumulation and monitoring urgency.

Injections are given on an empty stomach where possible. Food, particularly carbohydrates, raises somatostatin tone and blunts GH pulse amplitude. Waiting at least 90 minutes after a meal and 30 minutes before eating after injection is standard clinical guidance.

CJC-1295 Dosing: DAC vs. No DAC

The version matters substantially for protocol design.

CJC-1295 with DAC is dosed at 1 to 2 mg once weekly by subcutaneous injection. Its long half-life produces continuous GH elevation. This is convenient but reduces the pulsatile character of GH secretion, which some clinicians consider less physiologically desirable.

CJC-1295 without DAC (Mod GRF 1-29) is dosed at 100 to 300 mcg per injection, co-administered with ipamorelin in the same syringe or as sequential injections, 1 to 3 times daily. This preserves the pulsatile pattern and mirrors native GHRH kinetics more closely. Most clinical protocols pair ipamorelin with the no-DAC version for this reason.

Cycle Length and Off-Cycle Considerations

Common clinical practice runs 8 to 16 weeks on, followed by a 4 to 8 week off-cycle. There is no RCT evidence establishing an optimal cycle duration. The off-cycle period allows pituitary GHS-R and GHRH-R receptor density to recover and reduces the theoretical risk of desensitization. IGF-1 should be rechecked at the start of each new cycle.

Who Should Not Use This Stack

Absolute contraindications based on GH secretagogue class effects include:

• Active or history of hormone-sensitive malignancy (breast, prostate, colorectal, etc.)
• Active proliferative or severe non-proliferative diabetic retinopathy
• Pregnancy or breastfeeding
• Pediatric patients with open epiphyses (risk of skeletal dysplasia)
• Severe uncontrolled hypothyroidism (GH axis function depends on adequate thyroid status)
• Known hypersensitivity to either peptide

Relative contraindications requiring case-by-case clinical judgment include pre-existing insulin resistance, obesity with metabolic syndrome, a family history of acromegaly-associated comorbidities, and patients on concurrent glucocorticoid therapy (which blunts GH response and masks glucose signals).

Regulatory and Compounding Considerations

Neither ipamorelin nor CJC-1295 holds FDA approval for any indication in the United States. Both are used under compounding pharmacy regulations, which are governed by the FDA's 503A and 503B frameworks [8]. In 2024, the FDA added certain compounded peptides to its list of drugs that may not be compounded because they are essentially copies of approved drugs or lack demonstrated clinical necessity, signaling increased regulatory scrutiny of the compounding peptide market.

Patients and clinicians should confirm that any peptide product is sourced from an FDA-registered 503B outsourcing facility with certificates of analysis (CoA) verifying purity and sterility. Products sourced outside this framework carry unknown contamination and concentration risks.

Practical Safety Checklist for Clinicians

Before initiating the stack, the treating clinician should document:

1. Baseline IGF-1 within the age-adjusted normal range
2. No active malignancy on history or recent screening
3. Fasting glucose below 126 mg/dL and HbA1c below 6.5%
4. Informed consent including the absence of RCT data for this specific combination
5. Source of peptides (503B outsourcing facility preferred)
6. Monitoring schedule confirmed (week 8 IGF-1, week 12 metabolic panel)

If IGF-1 exceeds the upper normal limit at any monitoring visit, the clinical action is dose reduction first, then temporary discontinuation if the value does not normalize within 4 weeks of dose reduction.

Special Populations

Older Adults

GH axis activity declines with age, and older adults may show larger relative IGF-1 increases from the same peptide dose compared to younger users. Men and women over 60 should start at the low end of the dosing range (100 mcg ipamorelin, 100 mcg Mod GRF, once daily at bedtime) and monitor IGF-1 at 6 weeks rather than 8.

Women and Hormonal Interactions

Estrogen modulates GH secretion and IGF-1 clearance. Women on oral estrogen therapy (combined OCP or oral HRT) may show blunted IGF-1 responses compared to those on transdermal estrogen, a pharmacokinetic interaction documented with exogenous GH therapy [10]. This does not change the starting dose but does affect IGF-1 interpretation. Women experiencing oligomenorrhea on the stack should have prolactin rechecked, as ghrelin-pathway activation has a small but measurable effect on prolactin in some subjects [2].

Patients on Concurrent Peptide Therapy

Combining this stack with additional GH secretagogues (e.g., MK-677, sermorelin, GHRP-2) is not supported by safety data and should be avoided. Additive IGF-1 elevation from multiple secretagogue agents increases the likelihood of supra-normal IGF-1 and all associated risks.